Tag: rituximab

1. Among patients categorized as B-cell poor group via RNA sequencing, tocilizumab had a significantly higher response rate than rituximab. 2. Likelihood of adverse events and serious adverse events were comparable between both treatment groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Rheumatoid arthritis is a chronic autoimmune condition with considerable morbidity...

1. Rituximab was found to significantly reduce median time to remission in new-onset myasthenia gravis. 2. Rituximab appeared to outperform conventional immunosuppressant therapy in terms of need for rescue therapy and adverse effects resulting in discontinuation. Evidence Rating Level: 2 (Good) Myasthenia gravis (MG) is a serious neuromuscular disease, resulting from an autoreactive humoral...

1. In this randomized controlled trial involving patients with antineutrophil cytoplasmic antibody-associated vasculitis in complete remission, administration of rituximab for an additional 18 months was associated with a lower likelihood of relapse versus placebo. 2. Although the vast majority of patients in both groups reported at least 1 adverse event,...

Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19) 1. No association was found between angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use and test-positivity for COVID-19. Evidence Rating Level: 2 (Good) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the...

1. In this randomized control trial of neuromyelitis optica spectrum disorder (NMOSD) patients with aquaporin-4 antibodies (AQP4-IgG), those randomized to receive the eculizumab complement inhibitor experienced a lower relapse rate over 24 months than placebo treated patients. 2. Eculizumab patients more commonly experienced upper respiratory tract infections (URI) and headaches. Evidence...

1. Previously untreated chronic lymphocytic leukemia (CLL) patients experienced increased progression-free and overall survival when treated with ibrutinib-rituximab compared to current standard chemoimmunotherapy. 2. Rates of high grade adverse events were similar between treatment groups. Evidence Rating Level: 1 (Excellent)   Study Rundown: CLL is a common hematologic malignancy often treated with a...